Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.
IRB Barcelona PhD student Marcos Fernández is one of three researchers featured in the article published today in El Mundo, following Friday's ceremony in Madrid, where 68 young scientists received their "la Caixa" doctoral fellowships.
Since the end of 2016, this 25-year old Madrid native has been working towards his PhD degree in the Translational Control of Cell Cycle and Differentiation lab led by ICREA researcher Raúl Méndez. Marcos is studying protein synthesis in several types of tumours.